BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 15062170)

  • 1. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumor repopulation on radiotherapy planning.
    Wang JZ; Li XA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):220-7. PubMed ID: 15629615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
    Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
    Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
    Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
    Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B
    Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
    Cosset JM; Haie-Meder C
    Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
    Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
    Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the appropriate fraction number and size of the HDR brachytherapy for cervical cancer.
    Liu WS; Yen SH; Chang CH; Yang KM; Wu YP; Chen KY
    Gynecol Oncol; 1996 Feb; 60(2):295-300. PubMed ID: 8631555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose rate brachytherapy for prostate cancer.
    Hoskin P
    Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
    Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
    King CR; DiPetrillo TA; Wazer DE
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.